Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics (Nasdaq:CNTX) granted a non-qualified stock option to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Context Therapeutics (Nasdaq:CNTX) granted a non-qualified stock option to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4). The option covers 146,000 shares at an exercise price of $1.71, has a 10-year term, and vests over four years, subject to continued service.

Argus Jun 10 session

-4.61% close to close Open Argus

Details

News Market Reaction – CNTX

In the Jun 10 session, CNTX declined 4.61%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant covering 146,000 shares...

Analysis

This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant covering 146,000 shares at an exercise price of $1.71, vesting over four years. It follows a series of recent pipeline and licensing updates, including Fast Track status for CTIM-76 and a revised CT-202 license. Investors may focus more on upcoming clinical data and cash runway, while viewing this grant as a routine hiring and retention tool rather than a fundamental catalyst.

Key Figures

Inducement option size: 146,000 shares Option exercise price: $1.71 per share Option term: 10 years +3 more

Inducement option size

146,000 shares

Non-qualified stock option grant to a new employee

Option exercise price

$1.71 per share

Equal to CNTX Nasdaq closing price on June 8, 2026 grant date

Option term

10 years

Duration of the non-qualified stock option grant

Vesting period

4 years

Stock options vest over four years, subject to continued service

Initial vesting tranche

One-fourth of shares

Vests on the first anniversary of the grant date

Remaining vesting installments

36 monthly installments

Balance vests in thirty-six equal monthly installments after year one

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   Conference & option grant

   24h Move

   +13.3%

   Jefferies conference appearance and inducement option grant to a new employee.

2. May 18

   License amendment

   24h Move

   -0.5%

   Amended BioAtla CT-202 license into fully paid-up, non-terminable agreement.

3. May 06

   Q1 2026 earnings

   24h Move

   -3.3%

   Reported Q1 2026 financials, cash runway to mid-2027, and trial timelines.

4. Apr 08

   Board-related news

   24h Move

   +0.8%

   Neogen officer appointment highlighting a director who also serves on CNTX’s board.

5. Apr 02

   Fast Track designation

   24h Move

   +2.6%

   FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock option, nasdaq listing rule 5635(c)(4), exercise price

3 terms

non-qualified stock option financial

"Context has granted a non-qualified stock option award to purchase 146,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

nasdaq listing rule 5635(c)(4) regulatory

"granted ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"with an exercise price equal to the closing price of Context’s common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date (June 8, 2026) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date ($1.71 per share).

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with Context through the applicable vesting date.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option inducement grant did Context Therapeutics (CNTX) announce on June 9, 2026?

Context Therapeutics announced a non-qualified stock option inducement grant covering 146,000 shares for a new employee. According to Context Therapeutics, the grant was made outside its 2021 plan as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new CNTX stock options granted as an inducement?

The exercise price of the new Context Therapeutics stock options is $1.71 per share. According to Context Therapeutics, this equals the closing price of CNTX common stock on the June 8, 2026 grant date as reported by Nasdaq.

How do the Context Therapeutics (CNTX) inducement stock options vest for the new employee?

The Context Therapeutics inducement stock options vest over four years, subject to continued service. According to Context Therapeutics, one-fourth of the 146,000 shares vest on the first anniversary, with the remaining shares vesting in 36 equal monthly installments thereafter.

What is the term of the Context Therapeutics CNTX inducement stock option grant?

The Context Therapeutics inducement stock option grant has a 10-year term from the June 8, 2026 grant date. According to Context Therapeutics, the option remains exercisable during this period, subject to standard conditions and the employee’s continued service for vesting.

Why did Context Therapeutics grant CNTX stock options outside its 2021 Long-Term Plan?

Context Therapeutics granted the stock options outside its 2021 Long-Term Performance Incentive Plan as a hiring inducement. According to Context Therapeutics, the non-qualified options qualify under Nasdaq Listing Rule 5635(c)(4) as a material inducement for the new employee to accept employment.